Confirmed symposia for next year’s Summer Meeting of the British Association for Psychopharmacology [BAP] indicate an increasing defensiveness:
BAP ‘symposia’ are generally sponsored by the pharmaceutical industry.
BAP meetings continue to be accredited to provide continuing Medical Education for UK psychiatrists. I consider this accreditation as harmful.